Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes
June 23 2017 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines for patients with rare
neurological disorders, today announced that it will be added to
the Russell 2000®, 3000® and Microcap® Indexes, effective as of the
close of the market on Friday, June 23, 2017, following Russell’s
annual reconstitution of its comprehensive set of U.S. and global
equity indexes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell determines membership for its
equity indexes primarily by objective, market-capitalization
rankings and style attributes. The Russell 2000 Index measures the
performance of the small cap segment of the U.S. equity universe.
The Russell 2000 Index is a subset of the Russell 3000 Index
representing approximately 10 percent of the total market
capitalization of that index. The Russell Microcap Index represents
2,000 small cap and microcap stocks and captures the smallest 1,000
companies in the Russell 2000, in addition to 1,000 smaller
U.S.-based listed stocks.
About Ovid TherapeuticsOvid Therapeutics
(NASDAQ:OVID) is a New York-based, biopharmaceutical company using
its BoldMedicineTM approach to develop therapies that transform the
lives of patients with rare neurological disorders. Ovid’s drug
candidate, OV101, is currently in development for the treatment of
Angelman syndrome and Fragile X syndrome. Ovid has initiated the
Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a
Phase 1 trial in adolescents with Angelman syndrome or Fragile X
syndrome. Ovid is also developing OV935 in collaboration with
Takeda Pharmaceutical Company Limited for the treatment of rare
epileptic encephalopathies. Ovid expects to initiate a Phase 1b/2a
trial of OV935 to treat rare epileptic encephalopathies in
2017.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking StatementsThis press release
includes certain disclosures which contain “forward-looking
statements,” including, without limitation, statements regarding
the scope and timing of initiating a Phase 1b/2a trial of OV935 to
treat rare epileptic encephalopathies. You can identify
forward-looking statements because they contain words such as
“will,” “believes” and “expects.” Forward-looking statements are
based on Ovid’s current expectations and assumptions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in Ovid’s filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017, under the caption “Risk Factors.”
Ovid assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024